A Target Occupancy Study of Xanamem
Phase of Trial: Phase I
Latest Information Update: 26 Nov 2018
At a glance
- Drugs UE 2343 (Primary)
- Indications Alzheimer's disease
- Focus Pharmacodynamics
- 26 Nov 2018 Status changed from planning to recruiting, according to an Actinogen Medical media release.
- 03 Aug 2018 New trial record
- 30 Jul 2018 According to an Actinogen Medical medioa release, this trial is expected to begin in Q4 2018 and results are anticipated in Q2 2019.